Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Queensland to Co-Establish Global Vaccine Hub

In a bid to establish itself as a global mRNA vaccine hub, The Queensland government has partnered with a leading healthcare company to establish a world-first research centre in Brisbane. The AU$280 million Translational Science Hub will be established under an agreement between the company, the University of Queensland, Griffith University, and the Queensland Government.

The state’s Premier noted that Queensland will be the only jurisdiction in Australia to have a centre like this. She said that the Translational Science Hub will give them the platform to develop life-saving vaccines.

The Deputy Premier and Minister for State Development said the new Hub would help drive the development of new vaccines and healthcare solutions across the world. Through the Translational Science Hub, Queensland scientists will collaborate with global peers in the US and France on ground-breaking mRNA technology and vaccine development.

The Hub will bring more expertise, supply-chain capabilities, as well as clinical investigations to Queensland. It is expected to create up to 200 jobs for Queenslanders and strengthen the region’s biomanufacturing supply chain. mRNA technology is expected to deliver a new generation of vaccines that instruct certain cells to produce proteins that are recognised by the immune system to mount a defence.

The Minister for Science stated that Queensland is being recognised as a global research and innovation hub thanks to the government’s investment in state-of-the-art research facilities, talent attraction and partnerships between industry, academia and government.

She said that the agreement will make Queensland science even more competitive by accelerating the commercialisation of local research by linking university partners with a global industry leader to evaluate and develop new health technologies.

The government is also investing AU$17 million in the state budget to provide significant support to foster partnerships between universities and industry and accelerate the commercial application of major research being conducted in the state.

The Translational Science Hub in Queensland will work closely with the healthcare firm’s mRNA Centre of Excellence in France and the US to accelerate a new era of vaccine innovation, the firm’s Global Head of Vaccine Research and Development said.

The Vice-Chancellor and President, Griffith University, stated that Griffith is delighted to be part of the partnership building on the strengths and capabilities of the University’s existing biomedical leadership. The University’s researchers are internationally recognised for bringing disease-specific mRNA expertise to developing new vaccines and therapies while our Clinical Trial Unit is a leader in testing safety and efficacy.

The Vice-Chancellor, University of Queensland stated that the partnership builds on a commitment to bring the latest technologies to UQ’s internationally recognised vaccine and drug development programs. The shift in focus mRNA technologies was accelerated during the pandemic and UQ has invested in both the people and facilities to ensure mRNA for pre-clinical research can be developed and produced in Queensland.

The Translational Science Hub will be located across Queensland, using the laboratories and infrastructure of the University of Queensland, Griffith University, and the Translational Research Institute (TRI). The research is expected to start in Q1 2023 with an initial focus on a Chlamydia vaccine.

Chlamydia is the most common STI in the world with around 129 million infections a year. While Chlamydia can be treated, there is currently no vaccine to prevent infection. If left untreated it can lead to infertility and in pregnant women can result in foetal eye and lung infections.

The biomedical industry in Queensland contributes around AU$ 2.1 billion in gross value-added products and employs more than 12,000 people across the state. The industry is supported by the Queensland Biomedical 10-Year Roadmap and Action Plan.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and consulting services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,800 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently, and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity, and service. For more information, visit